Stay updated on First-Line Tarlatamab Combo in ES-SCLC Clinical Trial
Sign up to get notified when there's something new on the First-Line Tarlatamab Combo in ES-SCLC Clinical Trial page.

Latest updates to the First-Line Tarlatamab Combo in ES-SCLC Clinical Trial page
- Check3 days agoChange DetectedRevision label updated to v3.5.2; revision v3.5.0 was removed.SummaryDifference0.0%

- Check10 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check32 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0 is displayed on the page. This change reflects a minor version update with no apparent impact on content or user actions.SummaryDifference0.0%

- Check39 days agoChange DetectedPage revision updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check46 days agoChange DetectedNew date stamps and results-posting status were added (e.g., 'No Results Posted' on 2026-03-03), and older entries were removed. The overall study details, eligibility criteria, and planned interventions remain unchanged.SummaryDifference0.2%

- Check67 days agoChange Detected- Revision: v3.4.2 has been added. The government funding notice and Revision: v3.4.1 banner have been removed; no study content or eligibility information was changed.SummaryDifference0.3%

- Check74 days agoChange DetectedResults status updated from No Results Posted to Results Submitted, and the page revision shows Revision: v3.4.1. A government-funding status notice about NIH operations is also displayed.SummaryDifference0.3%

Stay in the know with updates to First-Line Tarlatamab Combo in ES-SCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the First-Line Tarlatamab Combo in ES-SCLC Clinical Trial page.